I4409

Fulvestrant

>98% (HPLC), PKC activator, powder

• Sinonimo/i: (7a,17b)-7-[9-[(4,4,5,5,5pentafluoropentyl)Sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol, Faslodex, ICI 182,780, ZD 182780, ZD 9238, ZM 182780
• Formula empirica (notazione di Hill): C₃₂H₄₇F₅O₃S
• Numero CAS: 129453-61-8
• Peso molecolare: 606.77
• UNSPSC Code: 51111800
• PubChem Substance ID: 329815373
• NACRES: NA.77
• MDL number: MFCD00903953
• Assay: >98% (HPLC)
• Form: powder

Proprietà

• Nome del prodotto: Fulvestrant, >98% (HPLC)
• assay: >98% (HPLC)
• form: powder
• solubility: DMSO: >5 mg/mL
• originator: AstraZeneca
• storage temp.: 2-8°C
• SMILES string: [H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc24
• InChI: 1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
• InChI key: VWUXBMIQPBEWFH-WCCTWKNTSA-N
• Gene Information: human ... ESR1(2099), ESR2(2100)

Descrizione

Application

Fulvestrant has been used:

• as an antagonist of estrogen receptor (ERα and ERβ) to reduce hepatocytes proliferation
• as an antagonist of ER for the suppression of estrogen responsive element in human breast cancer MCF-7 cells
• as anti-estrogen in breast cancer cell lines

Biochem/physiol Actions

Fulvestrant (ICI 182,780) is a selective estrogen receptor down-regulator (SERD). Fulvestrant is a high affinity estrogen receptor antagonist. IC₅₀ = 0.29 nM. Fulvestrant is the first "pure" antiestrogen with no agonistic activity both in vitro and in vivo.

Fulvestrant is a selective estrogen receptor down-regulator (SERD); high affinity estrogen receptor antagonist.

Fulvestrant is a 7α-alkylsulphinyl analog of 17β-oestradiol and is structurally different compared to other selective estrogen receptor (ER) modulators (SERMs). It reduces dimerization and nuclear localization of the estrogen receptor (ER). Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant is preferred for the treatment of women at their menopause having hormone-sensitive advanced breast cancer.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informazioni sulla sicurezza

• pictograms: GHS08,GHS09
• signalword: Danger
• hcodes: H360Df,H362,H410
• pcodes: P202 - P260 - P263 - P264 - P273 - P308 + P313
• Hazard Classifications: Aquatic Chronic 1 - Lact. - Repr. 1B
• Classe di stoccaggio: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)